marked.bio

Company

Transcenta Therapeutics

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

pembrolizumab 1osemitamab 1nivolumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

    Not yet recruiting Phase 3 Transcenta Therapeutics Starts 2027Primary completion 2029-10 NCT06093425

    pembrolizumaboxaliplatinleucovorinfluorouracil

    Positive CLDN18.2 expression in tumor tissue confirmed by the central laboratory at screening using CTA (Cl…

    Claudin 18.2 expressionGastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer

  2. A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1/2 Transcenta Therapeutics Started 2020Primary completion 2027-06 NCT04495296

    osemitamaboxaliplatincapecitabinepaclitaxelgemcitabinecisplatinnivolumab

    …pansion study: The subjects with positive CDLN18.2 expression in tumor tissue (defined as CLDN18.2 membranous staining ≥1+ in ≥10% of tumor cells by immunohistochemistry (IHC) in the centr…

    Claudin 18.2 expressionAdvanced Cancer